Online inquiry

IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3153MR)

This product GTTS-WQ3153MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets C3&C4 gene. The antibody can be applied in Cardiopulmonary bypass (CPB) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000064.4; NM_001002029.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 718; 721
UniProt ID P01024; P0C0L4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3153MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5420MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CD74-DOX (ADC)
GTTS-WQ9339MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA INCAGN-01876
GTTS-WQ4672MR IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986089
GTTS-WQ11267MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI4893
GTTS-WQ5231MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CB 2679d
GTTS-WQ7551MR IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GC33
GTTS-WQ5429MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CD74-DOX (ADC)
GTTS-WQ12037MR IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MNRP1685A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW